Sinsulin

Quick links to important sections

Sinsulin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinsulin

Sinsulin is a synthetic pharmaceutical agent and a prescription-only medicine whose active component is the established chemical compound, Oxazolam. This medication is a single-ingredient product, typically supplied as an oral preparation, such as a tablet or capsule, administered via the oral route.


Quick Facts: Sinsulin (Oxazolam)

Property Description
Active ingredient Oxazolam (C₁₉H₂₂ClN₃O₂)
Form Oral preparation (Tablet or Capsule)
Pharmacological class Anxiolytic
Common use Management of psychological tension and distress
Origin Synthetic chemical compound

What Type of Medicine is Sinsulin (Oxazolam)?

Sinsulin is classified pharmacologically as an anxiolytic, a functional category of medicine that belongs to the broader chemical group of Benzodiazepine derivatives. Its identity is centered on the active component, Oxazolam, which provides the drug's therapeutic effect. Oxazolam is defined by its molecular structure, C₁₉H₂₂ClN₃O₂. The drug's classification as an anxiolytic is based on its primary function to provide a calming effect, a use widely recognized and documented by global health authorities.


Understanding the Composition and Purpose of Sinsulin

The purpose of Sinsulin is to manage severe psychological tension and emotional distress by modulating activity in the Central Nervous System (CNS). The active ingredient, Oxazolam, acts on the GABAA receptors, serving as a positive allosteric modulator that enhances the effects of the brain’s main inhibitory neurotransmitter, Gamma-aminobutyric acid (GABA). This enhancement of GABA neurotransmission results in a powerful sedative-hypnotic and tranquilizing effect. This specific action is clinically recognized for its efficacy in rapidly easing symptoms of acute anxiety or restlessness, confirming the drug's goal to help stabilize CNS activity.

What side effects are possible with Sinsulin?

Possible Side Effects and Safety Information

The safety profile of Sinsulin (Oxazolam) is structured around adverse reactions and specific constraints documented in official regulatory labeling. These effects are generally categorized by frequency and the body system affected, ensuring clarity in the risk assessment.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are related to the Central Nervous System (CNS) depressant activity of the medicine. These are classified in official sources as Common and include drowsiness (somnolence), dizziness, vertigo, and headache. Less common reports include nausea, lethargy, slurred speech, and minor skin rashes. Rare adverse reactions documented in regulatory text include hepatic dysfunction, jaundice, and leukopenia.

Serious Safety Constraints and Risks

The official prescribing information includes explicit warnings regarding serious risks. These documented risks emphasize the potential for physical dependence and severe withdrawal reactions, which increase with higher doses and longer duration of use. Additionally, there is a risk of profound sedation and respiratory depression when Sinsulin is used concurrently with other CNS depressants, such as alcohol or opioids, as stated in regulatory documents.

Safety Domain Documented Consideration
Population Specific Older adults may exhibit increased sensitivity to CNS effects like sedation and ataxia, raising the risk of falls.
Time-Related Pattern Drowsiness is often more pronounced at the beginning of treatment and may lessen with continued use.
Safety Restrictions Contraindications include known hypersensitivity to benzodiazepines and caution is advised in patients with severe respiratory insufficiency.

These safety classifications provide a medically grounded description of the possible effects and constraints associated with Sinsulin, strictly reflecting the information in regulatory documents.

Overdose and Emergency Response

The official regulatory documents define Sinsulin (Oxazolam) overdose as primarily involving exaggerated Central Nervous System (CNS) depressant effects. Documented presentations range from milder signs like somnolence, confusion, lethargy, and slurred speech to more severe physiological consequences, including depressed reflexes.

The most serious outcomes described in the labeling include profound respiratory depression, severe hypotension, and the potential for coma and death, particularly when high doses are taken or when co-ingested with other CNS depressants. Immediate medical attention must be sought for any suspected overdose event; regulatory bodies mandate contacting emergency services promptly.

Official management protocols describe symptomatic and supportive treatment, focusing on the maintenance of a patent airway and continuous monitoring of vital signs (respiratory and cardiovascular function). The specific benzodiazepine antagonist, Flumazenil, is available for reversal; however, its use is cautioned against in certain situations (e.g., long-term use) due to the risk of precipitating seizures, as detailed in the prescribing information.

Regulatory sources note that elderly patients and individuals with hepatic impairment or chronic respiratory insufficiency are at an increased risk for severe adverse effects following an overdose exposure.

Therapeutic Uses of Sinsulin

Sinsulin (Oxazolam) is primarily used for its capacity to provide short-term symptomatic relief across several key domains of distress and anxiety. It is considered relevant in contexts involving heightened systemic burden and distress. This medication is used to help manage symptoms related to anxiety and acute alcohol withdrawal.

It is applied across domains where supportive symptom management is appropriate, primarily for conditions presenting with acute episodes and where symptoms may intensify temporarily. It is relevant in conditions characterized by periods of heightened symptoms, which include anxiety disorders and the symptomatic management of acute alcohol withdrawal syndrome.

“Sinsulin is relevant when supportive symptom management is appropriate, assisting patients with coping more steadily with difficult episodes.”


Quick Facts: Therapeutic Support

Quick Fact: Symptomatic Relief
Primary Context Applied when short-term symptomatic assistance is needed
Symptom Relief Used in situations involving certain distressing symptoms
Patient Benefit Contributes to improved comfort during periods of heightened symptoms

Regulatory References

  1. NIH MedlinePlus overview of Oxazepam

Eligibility and Restrictions for Use

Sinsulin (an analogue of human insulin, commonly known as a long-acting basal insulin) is indicated to help manage blood sugar (glycemic control) in adults and children with Type 1 and Type 2 Diabetes Mellitus.

Like all insulins, a healthcare professional must individualize the dose based on the patient's specific metabolic needs and frequent blood glucose monitoring. For patients with Type 1 diabetes, Sininsulin must be used in combination with a rapid- or short-acting insulin.


Contraindications

Sinsulin should not be used in patients with:

  • Hypoglycemia: During an episode of low blood sugar, the administration of insulin can worsen the condition, which may be life-threatening.
  • Hypersensitivity: A known allergy or severe allergic reaction to the active ingredient (insulin detemir) or any of the product's excipients.

Precautions and Specific Populations

Caution and close monitoring of dosage are necessary for patients with pre-existing conditions that may alter insulin's effect or increase the risk of adverse events. These include:

  • Kidney or Liver Impairment: These conditions can affect how insulin is cleared from the body.
  • Hypokalemia: Insulin can cause a shift of potassium into cells, potentially worsening low potassium levels.
  • Heart Failure: Concomitant use with certain medications (PPAR-gamma agonists, e.g., thiazolidinediones) may cause or exacerbate fluid retention and heart failure. Patients should be closely observed.

What should I know about interactions with other medicines?

The official regulatory profile for Sinsulin (Oxazolam) documents interactions that primarily involve additive pharmacodynamic effects and specific metabolic enzyme modification.

Co-administration with Opioid Analgesics and other Central Nervous System (CNS) depressants carries a major risk of additive CNS depression. This interaction is formally documented with a Boxed Warning in prescribing information due to the risk of profound sedation, respiratory depression, coma, and death. The regulatory restriction mandates that co-use with Opioids must be limited to the lowest effective dosages and minimum durations of treatment. Consumption of Alcohol is also associated with these additive CNS depressant effects.

Sinsulin is cleared by the Glucuronidation (UGT) enzyme system. Substances classified as UGT Inducers, such as Carbamazepine and Phenytoin, are documented to increase Oxazolam's metabolism. This metabolic interaction results in a reduced plasma concentration of Sinsulin and a potential loss of pharmacological efficacy.

Furthermore, the official profile notes specific population considerations: in elderly patients and individuals with hepatic or renal impairment, the medicine's clearance rate is physiologically slower. This slower removal is officially noted to result in increased systemic exposure to the drug.

Mechanism of Action

Receptor Activation and Glucose Repositioning

Sinsulin acts as an agonist by binding directly to the Insulin Receptor (IR) on the cell surface, initiating a signaling cascade primarily through the PI3K/Akt pathway. This molecular event drives the translocation of GLUT4 transporters to the cell membrane of muscle and fat cells. This mechanism facilitates a substantial increase in the uptake of glucose from the bloodstream into peripheral tissues.


Metabolic Storage and Production Regulation

The drug's mechanism operates across liver, muscle, and adipose tissues to promote anabolism (storage) while inhibiting catabolism (breakdown). In the liver, Sinsulin suppresses the enzymes and gene expression necessary for gluconeogenesis (new glucose production) while simultaneously stimulating the synthesis of glycogen (stored sugar). In fat tissue, it inhibits lipolysis (fat breakdown), resulting in a decreased blood glucose concentration and promoting the accumulation of nutrient reserves.

Dosage and Administration Information

Administration Overview

Sinsulin is administered via subcutaneous injection. This method involves delivering the medication into the fatty tissue layer just beneath the skin. Proper administration is essential to ensure the medication is absorbed consistently and effectively.

Preparation for Use

Before administration, the medication should be inspected visually. The solution must be clear and colorless. If the liquid appears cloudy, thickened, or contains visible particles, it should not be used. It is important to ensure the medication has reached a temperature suitable for injection, as injecting cold solution may cause discomfort.

Injection Sites

Commonly utilized areas for subcutaneous injection include:

  • Abdomen: Often preferred for its consistent absorption rates.
  • Thighs: The outer area of the thigh is typically used.
  • Upper Arms: The posterior aspect of the upper arm may be used if there is sufficient fatty tissue.

To maintain skin health and prevent the development of localized tissue changes, such as lumps or indentations, it is necessary to rotate the injection site with every dose. The same specific spot should not be used repeatedly.

Handling and Storage

Careful handling of the delivery device is required to maintain the integrity of the medication. Users should familiarize themselves with the mechanical components of their specific delivery system to ensure the technique is performed accurately.

After the injection is complete, the needle must be handled and disposed of according to standard biohazardous waste protocols to ensure environmental safety and prevent accidental injury. The delivery device should be stored as indicated by the specific storage requirements of the medication to maintain its stability.

Recent Clinical Evidence

Research evidence / Overview of Studies for Sinsulin

Evidence for Use in Anxiety Disorders and Psychological Tension

Research examining Sinsulin (Oxazolam) for conditions associated with psychological tension and anxiety has been conducted using short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time by comparing the drug against a placebo or other anxiolytic medications. The studies typically included adult participants diagnosed with conditions characterized by fluctuating or episodic manifestations of anxiety. Findings describe patterns observed in the studies related to measured differences in scores on the anxiety scales. However, evidence quality varies across studies, and some older trials described in systematic reviews have shown heterogeneity in their findings.

Evidence for Use in Acute Alcohol Withdrawal Syndrome (AWS)

Sinsulin was evaluated in research settings for conditions involving Acute Alcohol Withdrawal Syndrome (AWS). This research focused on conditions involving periods of heightened symptoms and associated with acute or disruptive episodes. The evidence is derived mainly from very short-term RCTs conducted during periods of increased symptom activity in adult in-patients. Studies monitored outcomes linked to physiological strain or stress, particularly tracking changes in the CIWA-Ar score (a scale for measuring withdrawal severity). The evidence for this acute condition was assessed in trials which reported high heterogeneity across different studies when comparing specific agents within the drug class.

Research on Extended Use and Long-Term Follow-up

The bulk of the clinical evidence that evaluated Sinsulin involves short-term follow-up durations, typically ranging from a few weeks to less than two months. The majority of research explored short-term symptom changes rather than extended treatment patterns. Because follow-up durations were limited, the scope of long-term effects remains to be fully established. There is limited information for long-term outcomes and the sustained symptomatic changes over many months or years of use.

Key Studies & References

  1. Label: OXAZEPAM capsule - DailyMed - NIH (US Regulatory Document)
  2. Public Assessment Report Scientific discussion Delipam (oxazepam) SE/H/2272/01-03/DC (EU/National Regulatory Document)
  3. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials
  4. Management of alcohol withdrawal syndromes in general hospital settings - The BMJ Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Sinsulin (FAQ)

Q: Do I have to take Sinsulin every day?

Sinsulin is intended to manage conditions that may require different treatment approaches. The oral component is typically used for short-term management, while the injectable component is part of a daily, scheduled regimen for blood sugar control. Official documents indicate that the rapid-acting injectable is generally administered in close proximity to mealtimes.

Q: What happens if I miss a dose of Sinsulin?

The official recommendation for a missed dose depends on the type of Sinsulin you are using. For the long-acting injectable, a partial dose may be taken if remembered late, depending on how close it is to the next scheduled dose. For the rapid-acting injectable, the dose should be taken if remembered shortly after the meal.

Q: Is Sinsulin safe to use long-term?

Official regulatory profiles indicate that the research evidence supporting Sinsulin is primarily derived from short-term follow-up studies, typically lasting only a few weeks. Due to these limited follow-up durations, the full scope of long-term effects remains to be fully established according to the documented evidence.

Q: Who is generally not eligible to take Sinsulin?

The official product information specifies several situations where Sinsulin should not be used. This includes people who have a known allergy or hypersensitivity to the medication's components. Additionally, the drug is contraindicated during episodes of low blood sugar (hypoglycemia) and in individuals with severe respiratory insufficiency.

Q: Can people with kidney problems use Sinsulin?

Yes, but official information indicates that caution is necessary for individuals with kidney or liver impairment. These conditions can slow down how the body clears the medication. Due to this potential for increased systemic exposure, the dosage may necessitate careful clinical monitoring and adjustment.

Q: Is it common for people to feel nauseous when they first start Sinsulin?

According to the official regulatory safety documents, nausea is classified as a less common adverse reaction. The most frequently reported effects are related to the central nervous system, such as drowsiness, dizziness, and headache.

Q: Are there any lifestyle changes recommended alongside taking Sinsulin?

Official documents primarily focus on mandatory precautions regarding co-use with other substances. This includes warnings about the serious risks of additive CNS depression when combining Sinsulin with Alcohol or Opioid Analgesics.

Q: Why might a doctor prescribe Sinsulin instead of another drug?

Research evidence indicates that Sinsulin was examined in randomized controlled trials (RCTs) against both a placebo and other anxiolytic medications to assess changes in symptoms. This type of comparative research provides information that a healthcare professional may consider when selecting a treatment regimen.

Q: Can Sinsulin be stopped suddenly?

Official prescribing information warns about the potential for developing physical dependence and experiencing severe withdrawal reactions. This risk is noted to increase with higher doses and longer duration of use, indicating that discontinuation is typically managed gradually under professional supervision.

Q: What should I do if I have an unexpected reaction to Sinsulin?

The patient counseling section of the label recommends contacting a healthcare provider or seeking emergency care immediately if a serious adverse reaction occurs, such as profound sedation or respiratory depression. This ensures prompt management of any potential safety issue.

Q: Is Sinsulin habit-forming or addictive?

Official safety constraints emphasize that Sinsulin carries a documented risk of physical dependence and the potential for severe withdrawal reactions. This risk is noted to be greater with higher doses and longer treatment duration.

Q: How long does it typically take before Sinsulin starts working?

The time it takes for Sinsulin to begin working depends on the formulation. The rapid-acting injectable component begins to lower blood glucose within about 15 minutes of administration. The oral component is recognized in clinical reports for rapidly easing symptoms of acute anxiety.

Q: Are there any common side effects people report when starting Sinsulin?

Official documents list common adverse reactions, including drowsiness, dizziness, vertigo, and headache. Of these, the regulatory label notes that drowsiness is often more pronounced when starting treatment and may lessen with continued use.

Q: What kind of severe side effects should I be aware of with Sinsulin?

Official regulatory documents describe several serious risks associated with Sinsulin. These include the potential for severe withdrawal reactions, profound sedation and respiratory depression, and episodes of severe hypoglycemia (low blood sugar). Rare reports of effects like hepatic dysfunction are also documented.

Q: Is it okay to take Sinsulin with vitamins or supplements?

Official interaction sections caution against combining Sinsulin with substances that may increase its sedative effects. Official information advises caution with supplements that have CNS depressant properties or those known to alter the body's enzyme system responsible for clearing the drug.

Q: What is the typical time frame for staying on Sinsulin?

Research evidence supporting Sinsulin is primarily derived from studies with short-term follow-up durations, typically lasting a few weeks to less than two months. The appropriate duration of therapy should be determined by the specific condition being managed.

Q: Is there a generic version of Sinsulin available?

The oral medication's active ingredient is the chemical compound Oxazolam. Official drug information indicates that the availability of generic products is determined by local regulatory approvals and market conditions in each country.

Q: Does Sinsulin cause weight changes?

Official product information indicates that insulin medications are generally associated with the potential for weight gain. Weight changes are not listed as a common or frequently reported adverse reaction for the oral anxiolytic component.

Q: What is the shelf life of Sinsulin?

The storage requirements differ based on the state of the medication. Unopened vials or pens must be kept in a refrigerator until their expiration date. In-use vials or pens are required to be stored at room temperature and discarded after the period specified on the packaging, which is often around 28 days.

Q: Why does the packaging for Sinsulin have a Black Box warning?

Official prescribing information includes a Boxed Warning to highlight the major risk of additive Central Nervous System (CNS) depression. This serious constraint is documented due to the risk of profound sedation, respiratory depression, and potentially coma when Sinsulin is co-administered with Opioid Analgesics and other CNS depressant medications.

Q: If Sinsulin is for a long-term condition, does it cure it?

The regulatory purpose of Sinsulin, according to official documents, is to manage conditions like blood sugar or psychological tension. It is described as a treatment for management and not as a cure for the underlying conditions.

Q: Can pregnant women or women who are breastfeeding use Sinsulin?

Official regulatory information indicates the benzodiazepine component is associated with evidence of human fetal risk (former Category D). The medication and its metabolite pass into breast milk, requiring infants to be monitored for effects like sedation. Use in these populations is subject to professional risk-benefit determination due to documented risks.

Q: Is Sinsulin a controlled substance?

Yes, the active ingredient in the oral anxiolytic component, Oxazolam, is classified in the United States as a Schedule IV controlled substance. This means its use and dispensing are regulated by federal law due to the potential for physical dependence.

Q: How does Sinsulin get eliminated from the body?

Official information about the drug's action indicates that the oral component is cleared from the body primarily through the Glucuronidation (UGT) enzyme system. This metabolic process can be affected by co-administered drugs.

Q: Can Sinsulin be split or crushed?

The oral anxiolytic component is supplied as a tablet or capsule. The regulatory documents do not contain instructions for altering the oral form (such as splitting or crushing), which suggests that the medication is intended to be swallowed whole.

Q: Is Sinsulin taken with or without food?

Official administration instructions for the rapid-acting injectable component specify that it is administered in close proximity to a meal. This is typically defined as within 15 minutes before starting a meal or immediately after beginning the meal.

Q: Does Sinsulin have different versions or strengths?

Sinsulin is supplied as both an injectable fluid (for the insulin component) and an oral preparation (tablet or capsule for the anxiolytic component). The oral product is typically available in multiple dosage strengths, which are listed in the official prescribing information.

Q: Is Sinsulin a stimulant?

No. Official product information classifies the oral component of Sinsulin as an anxiolytic, which belongs to the Benzodiazepine class. Its function is to provide a sedative-hypnotic and tranquilizing effect, which is the opposite of a stimulant.

Q: Does Sinsulin interact with grapefruit?

Official interaction warnings advise caution regarding the consumption of grapefruit juice. Grapefruit may interact with the oral component by inhibiting its metabolism, which can lead to elevated drug levels and potentially increase the risk of side effects.

How should Sinsulin be stored and disposed of?

Storage and Disposal Requirements for Sinsulin (Oxazolam)

Official regulatory documents define strict conditions for the storage and disposal of Sinsulin, an oral anxiolytic product.

Mandatory Storage Conditions

Condition Requirement
Temperature Store at room temperature (59 F to 86 F / 15 C to 30 C)
Protection Protect from freezing, excessive heat, and moisture
Container Keep in the original container, tightly closed
Safety Must be kept out of the reach of children

Disposal Instructions

Unused or expired Sinsulin must not be flushed down the toilet or poured into a drain. Disposal should be carried out through a medicine take-back program. If a program is unavailable, the medication must be mixed with an undesirable substance (such as used coffee grounds) and sealed in a plastic bag before being placed in the household trash. These procedures ensure safe handling and prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinsulin found in:

A-Z Index: